On December 30, 2020, a 专利申请 for a 制药 composition for treating TRPV1 activation-mediated diseases was completed in the 美国, bringing the total number of completed applications to three — 韩国, 美国, and PCT. Depending on registration status, the company plans to extend the 专利 to 中国, 欧洲, 日本, and other regions.
This 专利 covers the potential of TRPV1 in various pain conditions and allows for expansion into protein therapeutics, 基因治疗, and other modalities. It is expected to hold value as a use 专利 for various pain conditions upon registration.